Edwards Lifesciences Corporation (EW) Insider Trading Activity

NYSE$84.35
Market Cap
$49.52B
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
584 of 893
Rank in Industry
75 of 114

EW Insider Trading Activity

EW Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$17,953,158
37
100

Related Transactions

Markowitz WayneGM & SVP, Surgical
0
$0
2
$70,265
$-70,265
LORANGER STEVEN Rdirector
0
$0
1
$438,576
$-438,576
Chopra DaveenCVP, TMTT
0
$0
3
$486,228
$-486,228
STONE HEISZ LESLIEdirector
0
$0
2
$653,490
$-653,490
Lippis Daniel J.CVP, JAPAC
0
$0
9
$730,141
$-730,141
Wood Larry LGlobal President TAVR & Surg
0
$0
2
$1.37M
$-1.37M
Zovighian Bernard JCEO
0
$0
6
$4.35M
$-4.35M
Ullem Scott B.CVP, Chief Financial Officer
0
$0
6
$5.01M
$-5.01M
BOBO DONALD E JRCVP,Strategy/Corp Development
0
$0
8
$5.22M
$-5.22M

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Insider Activity of Edwards Lifesciences Corporation

Over the last 12 months, insiders at Edwards Lifesciences Corporation have bought $0 and sold $17.95M worth of Edwards Lifesciences Corporation stock.

On average, over the past 5 years, insiders at Edwards Lifesciences Corporation have bought $109,049 and sold $54.49M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 580 shares for transaction amount of $49,753 was made by Zovighian Bernard J (CEO) on 2024‑05‑06.

List of Insider Buy and Sell Transactions, Edwards Lifesciences Corporation

2026-01-09SaleLippis Daniel J.CVP, TAVR
1,019
0.0002%
$85.70
$87,332
-2.11%
2026-01-06SaleBOBO DONALD E JRCVP,Strategy/Corp Development
11,340
0.002%
$85.66
$971,429
-2.45%
2025-12-12SaleBOBO DONALD E JRCVP,Strategy/Corp Development
11,386.12
0.002%
$83.76
$953,748
+2.47%
2025-12-12SaleSTONE HEISZ LESLIEdirector
2,615
0.0004%
$83.41
$218,120
+2.47%
2025-12-12SaleLippis Daniel J.CVP, JAPAC
1,019
0.0002%
$84.03
$85,625
+2.47%
2025-12-11SaleChopra DaveenCVP, TMTT & Surgical
2,000
0.0003%
$84.38
$168,750
+0.88%
2025-12-10SaleBOBO DONALD E JRCVP,Strategy/Corp Development
11,340
0.0019%
$83.83
$950,581
+1.10%
2025-12-10SaleZovighian Bernard JCEO
3,863
0.0007%
$83.45
$322,367
+1.10%
2025-12-09SaleUllem Scott B.CVP, Chief Financial Officer
7,700
0.0013%
$84.47
$650,412
+1.87%
2025-12-08SaleZovighian Bernard JCEO
21,487
0.0037%
$85.21
$1.83M
+0.60%
2025-12-08SaleMarkowitz WayneCVP, JAPAC
583
0.0001%
$86.01
$50,144
+0.60%
2025-11-10SaleUllem Scott B.CVP, Chief Financial Officer
13,000
0.0022%
$83.08
$1.08M
+1.25%
2025-11-10SaleLippis Daniel J.CVP, JAPAC
1,020
0.0002%
$82.55
$84,196
+1.25%
2025-08-25SaleChopra DaveenCVP, TMTT
2,500
0.0004%
$81.95
$204,865
+2.70%
2025-08-18SaleWood Larry LGlobal President TAVR & Surg
8,950
0.0015%
$78.06
$698,679
+5.61%
2025-07-28SaleLippis Daniel J.CVP, JAPAC
4,114
0.0007%
$79.46
$326,901
+3.59%
2025-06-16SaleWood Larry LGlobal President TAVR & Surg
8,950
0.0015%
$75.23
$673,268
+6.79%
2025-06-03SaleZovighian Bernard JCEO
967
0.0002%
$77.32
$74,772
+1.56%
2025-06-02SaleBOBO DONALD E JRCVP,Strategy/Corp Development
2,570
0.0004%
$77.40
$198,911
+0.98%
2025-05-30SaleZovighian Bernard JCEO
16,099
0.0027%
$77.21
$1.24M
+0.74%
Total: 1153
*Gray background shows transactions not older than one year

Insider Historical Profitability

14.59%
Wood Larry LGlobal President TAVR & Surg
206900
0.0352%
$17.45M0102
LORANGER STEVEN Rdirector
60372
0.0103%
$5.09M11
<0.0001%
Ullem Scott B.CVP, Chief Financial Officer
39898
0.0068%
$3.37M041
Chopra DaveenCVP, TMTT & Surgical
32201
0.0055%
$2.72M020
BOBO DONALD E JRCVP,Strategy/Corp Development
31870
0.0054%
$2.69M0153
STONE HEISZ LESLIEdirector
30948
0.0053%
$2.61M06
Lippis Daniel J.CVP, TAVR
22002
0.0037%
$1.86M015
Markowitz WayneCVP, JAPAC
17563
0.003%
$1.48M03
Zovighian Bernard JCEO
8597
0.0015%
$725,119.09112
<0.0001%
Lemercier Jean-Luc MCVP, EMEACLA and JAPAC
173849
0.0296%
$14.66M024
Verguet Patrick BCVP, Europe
129137
0.022%
$10.89M091
KEHL JOHN H JRCVP, Strategy & Corp Dev
102839
0.0175%
$8.67M027
WANG HUIMINCVP, Japan & Intercontinental
99381
0.0169%
$8.38M0156
Cardis John Tdirector
91458
0.0156%
$7.71M05
BOWLIN MICHAEL Rdirector
81751
0.0139%
$6.9M010
GALLAHUE KIERANdirector
67219
0.0114%
$5.67M22
+27.32%
VALERIANI NICHOLAS Jdirector
63811
0.0109%
$5.38M11
<0.0001%
GARREN BRUCE PCVP, Public Affairs/Special Co
62748
0.0107%
$5.29M017
PYOTT DAVID E Idirector
48429
0.0082%
$4.08M16
+10.01%
MCNEIL BARBARA Jdirector
46454
0.0079%
$3.92M15
+33.89%
Abate Thomas MCVP, CFO
44393
0.0076%
$3.74M023
Szyman Catherine M.CVP, Critical Care
34814
0.0059%
$2.94M156
+31.99%
Solomon Carlyn DCVP, Critical Care & Vascular
31154
0.0053%
$2.63M018
INGRAM ROBERT ALEXANDERdirector
30541
0.0052%
$2.58M05
BESSLER ANITACVP
29410
0.005%
$2.48M07
NEAL PHILIP Mdirector
27333
0.0047%
$2.31M01
Marsh Martha H.
26777
0.0046%
$2.26M01
LOUCKS VERNON R JRdirector
17106
0.0029%
$1.44M02
FOSTER STUART LCVP, Critical Care / Vascular
17300
0.0029%
$1.46M08
Nevinny Corinne HCVP & Pres., Global Ops
16687
0.0028%
$1.41M013
SELLERS ROBERT W.A.SVP, Corporate Controller
13087
0.0022%
$1.1M018
Redmond Paul CCVP, Global Operations
12534
0.0021%
$1.06M014
Martin John AlexanderCVP, North America
11300
0.0019%
$953,155.0001
VON SCHACK WESLEY Wdirector
8000
0.0014%
$674,800.0036
+20.17%
MUSSALLEM MICHAEL Adirector
4486
0.0008%
$378,378.920239
LINK WILLIAM J PHDdirector
4722
0.0008%
$398,300.7005
McCauley Christine ZCVP, Human Resources
4234
0.0007%
$357,137.9001
WOODGRIFT RANDEL WILLIAMCorp VP, Manufacturing Ops
3349
0.0006%
$282,488.1504
REINDL ROBERT CCVP, H.R. and Communications
1124
0.0002%
$94,809.40023
*Gray background shows insiders who have made transactions during last year

EW Institutional Investors: Active Positions

Increased Positions550+39.63%43M+8.45%
Decreased Positions567-40.85%46M-9.07%
New Positions104New6MNew
Sold Out Positions107Sold Out6MSold Out
Total Postitions1,371-1.22%500M-0.62%

EW Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$6M12.13%70.36M+365,581+0.52%2025-09-30
Blackrock, Inc.$4.63M9.36%54.29M-1M-2.43%2025-09-30
State Street Corp$2.19M4.42%25.62M-14,746-0.06%2025-09-30
Jpmorgan Chase & Co$2.14M4.32%25.06M-2M-6.41%2025-09-30
Wellington Management Group Llp$1.78M3.59%20.8M+977,933+4.93%2025-09-30
Bank Of New York Mellon Corp$1.62M3.28%19.01M+1M+8.09%2025-09-30
Fmr Llc$1.24M2.51%14.58M+12M+476.71%2025-09-30
Jennison Associates Llc$1.19M2.41%13.96M+2M+19.6%2025-09-30
Geode Capital Management, Llc$1.1M2.21%12.84M+114,729+0.9%2025-09-30
Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt$788,466.001.59%9.24M+110,840+1.21%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.